Supportive mistletoe therapy in a patient with metastasised neuroblastoma.

Therapies of complementary and alternative medicine (CAM) are used increasingly in paediatric oncology. We present and discuss the influence of supportive mistletoe therapy on factors, such as quality of life, physical ability and performance, and course of disease based on the case of a female patient diagnosed at age 18 with metastasised neuroblastoma, which responded insufficiently to chemotherapy.

Safety of intravenously applied mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer.

Background: Mistletoe extracts have anti-tumor properties and are approved for subcutaneous use in cancer patients. Data on Intravenous application are limited.

Methods: An aqueous extract from pine-mistletoe was used to investigate maximum tolerable dose (MTD) and safety of intravenous application.

[Favourable course of persisting malignant ascites].

Malignant ascites is a frequent complication in oncological diseases. There are no standard therapies for any primary tumour. We report the case of a woman, aged 49 years at the time of primary diagnosis, who suffered from recurrent ascites resulting from liver metastasis of breast cancer.

In vitro response of stimulated B-CLL lymphocytes of patients treated with Viscum album L. extracts.

Background: Extracts from Viscum album (VA-E) have been shown to induce apoptosis and immunoactivation. To exclude possible B-CLL propagating effects, the in vitro reactions of cultured peripheral blood B-CLL cells were analysed.

Patients And Methods: Intracellular expression of apoptosis-associated mitochondrial Apo2.